Loading...

PRAX PRAXIS PRECISION MEDICINES INC Other Situations 8-K Filing

PRXS

PRX

PRAXIS PRECISION MEDICINES INC

(PRAX)

2025 8-K

Financial Results Announced

Board Appointments

Management Changes

Stock Offering Details

Financial Update

FDA Breakthrough Designation

FDA Meeting Update

FDA Meeting Success

Financial Results

FDA Meeting Granted

Stock Offering Announcement

Positive Trial Results

Sales Agreement Update

New Product Launches

Pre-Market Approval

Investor Events

Financial Statements

Financial Results

Financial Update

Q3 Earnings Report

Executive Changes

EMBOLD Study Results

Financial Results

Annual Meeting Approval

Financial Results Announcement

Underwriting Agreement for ...

Phase 2a Study Results

Financial Results and Corpo...

Underwriting Agreement

Termination of Sales Agreement

Financial Results

Agreement for Stock Sale

Reverse Stock Split and Upd...

Reverse Stock Split

Financial Results Announcement

Special Meeting of Stockhol...

Financial Results and Corpo...

Underwriting Agreement for ...

Termination of Sales Agreement

Annual Meeting of Stockholders

FDA Meeting Outcome

Phase 1 Study Results

Regulation FD Disclosure

Departure of Chief Commerci...

SVB Deposit Accounts

Essential1 Study Results

Financial Results and Corpo...

External Links:

On May 2, 2025, Praxis Precision Medicines updated investors on its programs, including positive results from the EMBOLD study showing sustained seizure reduction in patients treated with relutrigine, and plans for a Phase 3 trial with 160 participants. They also announced plans to advance the PRAX-100 program targeting autism-related mutations.

AI Assistant

PRAXIS PRECISION MEDICINES INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.